IDXX rides on strong CAG Diagnostics momentum and growing global software adoption, but currency pressure and solvency risks cloud the outlook.

IDEXX Laboratories, Inc. IDXX is set to release fourth-quarter 2025 results on Feb.2, before the opening bell. In the last ...

IDEXX Laboratories (NASDAQ:IDXX) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

Idexx LaboratoriesIDXX is the IBD Stock of the Day for Friday. Shares of the maker of animal diagnostics tools are trading within a flat base following a strong run late last year. The Maine-based ...

IDEXX Laboratories Inc (NASDAQ:IDXX) reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the consensus of $2.40. The pet healthcare company reported sales of $954.3 million, ...

A substantial insider activity was disclosed on February 12, as Erickson, Executive Vice President at IDEXX Laboratories (NASDAQ:IDXX), reported the exercise of a large sell of company stock options.